PIONEER REAL Saudi Arabia: A multicentre, prospective, real-world study of once-daily oral semaglutide use in adults with type 2 diabetes in Saudi Arabia.

ABSTRACT:

Aim

PIONEER REAL Saudi Arabia investigated real-world clinical outcomes associated with the use of once-daily oral semaglutide in adults with type 2 diabetes (T2D).

Materials and methods

This was a 34- to 44-week multicentre, prospective, open-label study in adults with T2D, who were treatment-naive to injectable glucose-lowering medication and initiated oral semaglutide in routine clinical practice. The primary endpoint was change from baseline to end of study (EoS) in glycated haemoglobin (HbA1c). Secondary and exploratory endpoints included changes in body weight (BW) and waist circumference (WC) from baseline to EoS. Treatment satisfaction was assessed using the Diabetes Treatment Satisfaction Questionnaire-status (DTSQs) and change (DTSQc) tools.

Results

In total

SUBMITTER: ElBadawi H 

PROVIDER: S-EPMC12803558 | biostudies-literature | 2026 Feb

REPOSITORIES: biostudies-literature